AstraZeneca's long-acting C5 complement inhibitor Ultomiris has been launched in China.

AstraZeneca announced that the long-acting C5 complement inhibitor Ultomiris has officially launched in China, used in combination with conventional treatments for adult patients with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies, as well as for adult patients with neuromyelitis optica spectrum disorders who are positive for anti-aquaporin-4 antibodies.